WO2014103957A1 - Aav変異体 - Google Patents
Aav変異体 Download PDFInfo
- Publication number
- WO2014103957A1 WO2014103957A1 PCT/JP2013/084336 JP2013084336W WO2014103957A1 WO 2014103957 A1 WO2014103957 A1 WO 2014103957A1 JP 2013084336 W JP2013084336 W JP 2013084336W WO 2014103957 A1 WO2014103957 A1 WO 2014103957A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aav
- seq
- capsid protein
- peptide
- aav2
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- the present invention relates to a nucleic acid encoding a variant of an adeno-associated virus (AAV) capsid protein, an AAV particle containing the capsid protein variant, and a method for producing a transgenic cell using the particle.
- AAV adeno-associated virus
- AAV is a virus whose genome is a 4.7 kb single-stranded DNA containing two open reading frame rep genes and a cap gene.
- the rep gene encodes four types of proteins (Rep78, Rep68, Rep52, and Rep40) necessary for genome replication
- the cap gene consists of three types of capsid proteins (VP1, VP2, VP3) assembled for viral capsid formation.
- AAP Assembly-Activating Protein
- AAV replication in nature depends on the presence of helper viruses such as adenovirus and herpes virus. In the absence of helper virus, AAV is maintained in its episome or integrated into the host chromosome and becomes latent. At present, more than 100 AAV serotypes and clades (Non-patent Document 1) have been identified, but AAV2 is being developed as a gene delivery vector.
- AAV-based vectors have been shown to have many advantages. Since wild-type AAV is non-pathogenic and has no pathogenic relationship with any known disease, AAV-based vectors are said to be extremely safe. In addition, AAV has a high efficiency of gene transfer.
- AAV ⁇ By long-term stable gene transfer to various target organs and target cells by administration of AAV particles.
- genes can be introduced into skeletal muscle, liver (hepatocytes), heart (cardiomyocytes), nerve cells, pancreatic gland cells, and islet cells with high efficiency.
- AAV has a track record of use in human clinical trials.
- attempts have been made to modify the AAV capsid protein to change AAV cell tropism and to avoid removal of AAV particles by neutralizing antibodies.
- AAV capsids that are directed to specific organs and cells such as glial cells, airway epithelial cells, coronary artery endothelial cells or lungs, and directed to tumor cells such as glioblastoma, melanoma, lung cancer or breast cancer
- An AAV capsid having a slag has been prepared (Non-patent Document 2).
- An object of the present invention is to provide an AAV capsid protein mutant having directivity to the heart and immune organs, particularly lymph nodes, and to provide a method for efficiently introducing genes into the lymph nodes.
- an AAV capsid protein having an amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 24, and SEQ ID NO: 30 in the sequence listing.
- AAV particles containing them were made to complete the present invention.
- AAV adeno-associated virus
- a recombinant DNA comprising the nucleic acid according to any one of [1] to [3], [5] A cell comprising the nucleic acid according to any one of [1] to [3] or the recombinant DNA according to [4], [6] AAV particles comprising an AAV capsid protein variant containing a peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 24 and SEQ ID NO: 30 in the sequence listing; [7] The AAV particle according to [6], wherein the AAV capsid protein is derived from AAV2.
- AAV particles containing an AAV capsid protein variant containing a peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 24 and SEQ ID NO: 30 in the sequence listing are brought into contact with cells.
- a method for producing a transgenic cell comprising the step of: [10] The method according to [9], wherein the AAV capsid protein is derived from AAV2.
- the method according to [9] wherein the peptide is contained at a position following amino acid number 588 of VP1 of AAV2.
- the present invention provides a gene transfer system useful for gene transfer into the heart and immune organs.
- the AAV particles of the present invention are highly cell-oriented to immune organs, particularly lymph nodes, and can strongly express the introduced gene.
- Adeno-associated virus refers to small viruses that infect primate animals including humans and other mammals belonging to the Parvoviridae family and the Dependovirus genus.
- Adeno Associated Virus is abbreviated as AAV.
- AAV has an icosahedral outer shell (capsid) having no envelope and one single-stranded DNA inside thereof.
- AAV includes wild type viruses and derivatives thereof, and includes all serotypes and clades except where specifically noted.
- vector refers to a molecule or an association of molecules that can be used to mediate delivery of a polynucleotide to a cell, including or associated with a polynucleotide.
- examples include vector DNA such as plasmid vectors and phage vectors, viral vector particles, liposomes, and other gene delivery vehicles, all of which are included in the vectors unless otherwise specified.
- the “capsid protein” is a protein encoded by a cap gene existing in the AAV genome and means a protein constituting the AAV capsid.
- the wild type AAV genome encodes three types of capsid proteins, and VP1, VP2 and VP3 exist. In the present specification, any of VP1, VP2 and VP3 is included in the capsid protein.
- nucleic acid encoding AAV capsid protein variant contains a peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 24 and SEQ ID NO: 30 in the sequence listing A nucleic acid encoding a mutant AAV capsid protein.
- the AAV capsid protein variants encoded by the nucleic acids of the present invention are type 1 AAV (AAV1), type 2 AAV (AAV2), type 3 AAV (AAV3A, AAV3B, etc.), type 4 AAV (AAV4), type 5 AAV (AAV5) ), 6 type AAV (AAV6), 7 type AAV (AAV7), 8 type AAV (AAV8), 9 type AAV (AAV9), 10 type AAV (AAV10), 11 type AAV (AAV11), avian AAV, bovine AAV, Inserting the peptide into any AAV capsid protein, such as canine AAV, horse AAV, sheep AAV, or replacing part of the amino acid sequence of the AAV capsid protein with a peptide (ie, including the peptide in the AAV capsid protein) Can be prepared.
- the AAV2 capsid protein can be particularly preferably used.
- the peptide contained in the AAV capsid protein has an amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 24 and SEQ ID NO: 30 in the sequence listing.
- a spacer sequence may be added to the N-terminus and / or C-terminus of the peptide.
- the spacer sequence is preferably 1 to 5 amino acid residues.
- the amino acid of the spacer sequence is not particularly limited, but for example, an amino acid selected from the group consisting of glycine, alanine and serine can be used.
- AAV's VP1, VP2, and VP3 can be used as the AAV capsid protein containing the peptide. Only VP1, VP2 or VP3 may contain the peptide, and all capsid proteins of VP1 to VP3 may contain the peptide. Furthermore, you may make it contain in two types of capsid proteins like the combination of VP1 and VP2, VP2 and VP3, VP1 and VP3. VP1 to VP3 are encoded in the cap gene region of the AAV genome. As one embodiment of the present invention, a mutation can be introduced into all of VP1 to VP3 by containing a peptide in a region common to VP1 to VP3.
- a gene encoding VP1, VP2, or VP3 can be prepared separately from the cap gene region of AAV, and a mutation can be introduced into this gene.
- treatment may be performed so that the capsid protein corresponding to the capsid protein encoded by the gene into which the mutation has been introduced is not expressed from the cap gene region of AAV.
- the position containing the peptide is preferably a position following amino acid number 588, that is, after amino acid number 588 in the case of VP1 of AAV2.
- the amino acid number 588 of AAV2 VP1 corresponds to amino acid number 451 of VP2 of AAV2 and amino acid number 386 of VP3 of AAV2.
- those skilled in the art can easily identify the amino acids of serotypes other than AAV2 and the capsid protein of clade AAV corresponding to the amino acid number 588 of VP1 of VP1 of AAV2.
- amino acid number 588 of VP1 of AAV2 is number 589 for AAV1, number 590 for AAV7, and number 591 for AAV8.
- the AAV capsid protein variant encoded by the nucleic acid of the present invention has an amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 24 and SEQ ID NO: 30 in the wild type AAV capsid protein.
- it may be a protein in which one to several amino acids are inserted, added, substituted or deleted.
- control sequences include promoter sequences, polyadenylation signals, transcription termination sequences, upstream regulatory domains, origins of replication, internal ribosome entry sites (IRES), enhancers and the like.
- Promoter sequences include inducible promoter sequences and constitutive promoter sequences.
- the control sequence may be unique or exogenous to AAV from which the capsid protein is derived, and may be a natural sequence or a synthetic sequence. Such recombinant DNA capable of expressing an AAV capsid protein variant is also encompassed by the present invention.
- the recombinant DNA of the present invention is useful for delivering the nucleic acid of the present invention to cells in vitro, in vitro and in vivo, and conferring the ability to express the AAV capsid protein variant on the cells.
- the cells to which the nucleic acid of the present invention has been delivered are useful for producing AAV particles.
- Such recombinant DNA can in particular be used to deliver or introduce the nucleic acids of the invention into animal cells, more preferably mammalian cells.
- the recombinant DNA of the present invention can be prepared by retaining the nucleic acid of the present invention in DNA used as a vector.
- DNA used as a vector for example, plasmid DNA, phage DNA, transposon, cosmid DNA, episomal DNA, and viral genome can be used.
- the present invention also provides a host cell containing the nucleic acid of the present invention, specifically the recombinant DNA of the above (1), for example, an isolated host cell. Isolated cells are, for example, cell lines maintained in vitro.
- the host cell of the present invention is useful for producing the AAV particle of the present invention as described below. When the host cell of the invention is used to produce AAV particles, it may be referred to as “packaging cell” or “producer cell”.
- the recombinant DNA of the present invention described in (1) above may be integrated into the genome, and the recombinant DNA is intracellularly expressed so as to transiently express the AAV capsid protein mutant. May be held.
- Introduction of the recombinant DNA of the present invention into a host cell can be performed by a known method. For example, electroporation, calcium phosphate precipitation, direct microinjection into cells, liposome-mediated gene transfer, nucleic acid delivery using a high-speed particle gun, and the like can be used.
- electroporation calcium phosphate precipitation
- direct microinjection into cells liposome-mediated gene transfer
- nucleic acid delivery using a high-speed particle gun and the like
- an infection method suitable for the vector may be selected.
- the recombinant DNA of the present invention is stably introduced into the host cell chromosome or transiently introduced into the host cell cytoplasm.
- selection markers such as selection markers such as neomycin resistance gene (encoding neomycin phosphotransferase), hygromycin B resistance gene (encoding aminoglycoside phosphotransferase (APH))can be ligated to the recombinant DNA of the present invention.
- Suitable mammalian cells include, but are not limited to, primary cells and cell lines. Suitable cell lines include 293 cells, COS cells, HeLa cells, Vero cells, 3T3 mouse fibroblasts, C3H10T1 / 2. Examples include fibroblasts, CHO cells, and cells derived from these cells.
- AAV particles containing an AAV capsid protein containing the amino acid sequence encoded by the nucleic acid of the present invention are derived from SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 24 and SEQ ID NO: 30 in the sequence listing.
- the AAV particles can be produced by the host cell described in (2) above.
- the AAV particles of the present invention are directed to the heart (myocardium), immune organs (immune cells), particularly lymph nodes, and are useful for gene transfer into para-aortic and / or femoral lymph nodes.
- the gene introduced by the AAV particles of the present invention is strongly expressed in the tissues, organs and cells.
- AAV particles can be produced using cells containing several components necessary for the production of AAV particles as packaging cells.
- the first component is a recombinant AAV vector genome (also called an expression vector) that can be replicated and packaged into AAV particles in a host cell.
- the recombinant AAV vector genome contains the desired heterologous polynucleotide and an AAV inverted terminal repeat (ITR) sequence on each side, ie, 5 'and 3'.
- the desired heterologous polynucleotide can have regulatory sequences for its expression.
- the base sequence of the ITR sequence is known. For example, for the ATR sequence of AAV2, Kotin R.I. Reference can be made to M et al., Human Gene Therapy, Volume 5, pages 793-801, 1994.
- an ITR sequence an ITR sequence derived from any of various AAV serotypes such as AAV1, AAV2, AAV3, AAV4, AAV5 and AAV7 can be used.
- the ITR sequence used in the present invention may be a sequence derived from wild-type AAV, and may be altered by nucleotide insertion, deletion or substitution.
- the ITR sequence allows replication of the recombinant AAV vector genome in the presence of the Rep protein, allowing integration into the capsid particle during AAV particle formation.
- Desired heterologous polynucleotides that can be loaded on the AAV particles of the present invention are generally less than about 5 kilobases (kb) in size, eg, genes encoding desired proteins that are missing or lost to the recipient, desired A desired nucleotide sequence encoding a gene encoding a protein having a biological or therapeutic action (eg, antibacterial, antiviral or antitumor action), an RNA inhibiting or reducing the production of harmful or undesirable proteins, antigen
- the nucleotide sequence encoding the sex protein can be appropriately set according to the purpose.
- the recombinant AAV vector genome lacks the cap gene region and / or the rep gene region, and the AAV particles packaged with the recombinant AAV vector genome of this embodiment are infected cells. In the AAV particle alone by itself.
- the second component necessary for the production of AAV particles is a construct that provides the AAV helper function.
- This construct encodes an AAV-derived gene that provides the AAV gene product necessary for the formation of AAV particles. That is, it includes one or both of the rep gene region and the cap gene region which are major AAV ORFs.
- AAV capsid protein mutation containing a peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 24 and SEQ ID NO: 30 in the sequence listing for producing the AAV particles of the present invention
- the nucleic acid encoding the body is used as the cap gene.
- the host cell of the present invention described in (2) above having the ability to express this mutant can be used for the production of AAV particles.
- AAV particles have an outer shell composed of a large number of capsid proteins, but all capsid proteins may be mutants, some of which may be mutants and the rest may be wild-type capsid proteins. Furthermore, the capsid protein variant contained in the AAV particles of the present invention may be one type of variant or multiple types of variants.
- the AAV rep gene is contained in the rep gene coding region, and includes genes encoding the replication proteins Rep 78, Rep 68, Rep 52, and Rep 40. These Rep expression products have been shown to have many functions, including recognition of AAV genomic DNA origins of replication, binding and nicking, DNA helicase activity and transcriptional changes of AAV-derived promoters.
- helper virus function also called an accessory function
- Adenovirus is generally used for introduction of the helper function, but viruses such as type 1 or type 2 herpes simplex virus and vaccinia virus can also be used.
- viruses such as type 1 or type 2 herpes simplex virus and vaccinia virus can also be used.
- the host cell is infected with the virus as a helper virus.
- adenoviruses that do not exhibit late gene expression may be used because only adenovirus early gene expression is required for AAV particle packaging.
- Adenovirus mutants that lack late gene expression eg, ts100K or ts149 adenovirus mutants) can be used.
- nucleic acid construct that provides a helper virus function can be prepared and introduced into a host cell using a nucleic acid necessary for the helper virus function isolated from the helper virus.
- a construct that provides helper virus function comprises a nucleotide sequence that provides one or more helper virus functions and is provided to the host cell in the form of a plasmid, phage, transposon, cosmid or other virus.
- AAV particles In order to produce AAV particles, (a) the step of introducing the vector genome of recombinant AAV, which is the first component, into a host cell, and (b) the construct that provides the AAV helper function, which is the second component, A step of introducing into a cell; and (c) a step of introducing a helper virus function as a third component into a host cell. These steps may be performed simultaneously or sequentially. The order of (a) to (c) may be any order.
- the expression product of the rep gene excises and replicates the vector genome of the recombinant AAV.
- the expressed capsid protein forms a capsid, and the vector genome of recombinant AAV is packaged into the capsid to produce AAV particles. And when this host cell expresses an AAV capsid protein variant, the AAV capsid protein variant is contained in the outer shell of the produced AAV particle.
- AAV particles can be isolated and purified from host cell culture supernatants and cell lysates using various purification methods such as CsCl density gradient centrifugation.
- a virus for example, a step of separating AAV particles and helper virus based on size may be added.
- AAV particles can also be separated from helper virus based on the difference in affinity for heparin.
- the remaining helper virus can be inactivated using a known method.
- adenovirus can be inactivated by heating at a temperature of about 60 ° C., for example for 20 minutes or longer. Since AAV particles are extremely heat-stable, this treatment is effective for selective removal of adenovirus used as a helper virus.
- AAV particle of the present invention obtained by the above (3) is used for delivering a desired heterologous polynucleotide to cells for gene therapy and other purposes.
- AAV particles are introduced into cells either in vivo or in vitro. When introducing in vitro, AAV particles are introduced into contact with cells obtained from a living body. These cells can also be transplanted into a living body. When cells are introduced into a living body, various techniques such as intramuscular, intravenous, subcutaneous and intraperitoneal administration can be used by formulating as a pharmaceutical composition.
- AAV particles are formulated as a pharmaceutical composition and generally administered parenterally (eg, administered by intramuscular, subcutaneous, intratumoral, transdermal, intrathecal, etc. route of administration).
- a pharmaceutical composition comprising AAV particles includes a pharmaceutically acceptable carrier and optionally other drugs, pharmaceutical agents, stabilizers, buffers, carriers, adjuvants, diluents, and the like.
- Preparation Example 1 Construction of pAAV-AsRed2 Using the pAsRed2-C1 Vector (manufactured by Clontech) as a template, a fragment of about 1.6 kb with a restriction enzyme NotI recognition site added upstream of the CMV promoter and downstream of the polyA signal Obtained by. This PCR product was treated with NotI (Takara Bio Inc.) to obtain insert DNA. On the other hand, pAAV-MCS Expression Vector (manufactured by CELL BIOLABS) was treated with NotI to prepare a fragment of about 2.9 kb, which was used as a vector.
- the insert DNA was ligated to this vector using DNA Ligation Kit ⁇ Mighty Mix> (manufactured by Takara Bio Inc.). Coli HST08 Premium Competent Cells (manufactured by Takara Bio Inc.) were transformed. Among the plasmid DNAs extracted from the obtained clones, pAAV-AsRed2 was inserted from the upstream in the order of CMV promoter-AsRed2-MCS-polyA signal.
- a plasmid vector pAV1 (ATCC Number: 37215) carrying the AAV2 genome was extracted from Escherichia coli HB101 of a general purpose host (Distribution host).
- AAV2 genomic DNA (about 4.7 kb) was excised from the extracted plasmid with restriction enzyme BglII (Takara Bio Inc.). This genomic DNA was inserted into pUC118 BamHI / BAP (manufactured by Takara Bio Inc.), and the resulting plasmid DNA was designated as AAV2WG / pUC118.
- AAV2WG / pUC118 was treated with a restriction enzyme ScaI (manufactured by Takara Bio Inc.) to obtain a fragment of about 0.8 kb containing the 1190th to 2017th bases of the cap gene. This fragment was inserted into pUC118 HincII / BAP (manufactured by Takara Bio Inc.), and the resulting plasmid DNA was designated as Cap-ScaI / pUC118.
- the 1759th to 1761th base sequence AAC (N) of the Cap gene of Cap-ScaI / pUC118 is converted into CAG (Q) using PCR, and GGC is used as a spacer between the 1764th and 1765th bases.
- CAAG as the stuffer
- 10 bases of GCC as the spacer
- CAA (Q) GCA (A) GCT (A) are converted to CAG (Q) GCG (A) GCC (A), (A letter in parentheses indicates an encoded amino acid).
- SfiI and spacers two recognition sites for the restriction enzyme SfiI and spacers, stuffers and spacers sandwiched between the SfiI recognition sites were inserted.
- the base sequence before and after the 1756th to 1773th conversion of the Cap gene is shown in FIG. 1, the base sequence before conversion is shown in SEQ ID NO: 1 in the sequence listing, and the base sequence after conversion is shown in SEQ ID NO: 2.
- Cap-ScaI-S4 / pUC118 The plasmid DNA after the base sequence conversion was named Cap-ScaI-S4 / pUC118.
- the Cap gene portion of Cap-ScaI-S4 / pUC118 was amplified by PCR for In-Fusion Cloning to obtain a fragment of about 0.8 kb, which was used as insert DNA.
- the base sequence before conversion is shown in SEQ ID NO: 5, and the base sequence after conversion is shown in SEQ ID NO: 6.
- the plasmid DNA thus obtained was treated with ScaI (manufactured by Takara Bio Inc.) to obtain a linear vector lacking about 0.8 kb, which is a part of the Cap gene. This was used as a linear vector for In-Fusion Cloning.
- insert DNA was inserted into the linear vector using In-Fusion (registered trademark) HD Cloning Kit (Clontech) and Cloning Enhancer (Clontech), and directional cloning was performed.
- the plasmid DNA thus obtained was designated as AAV2WG-Cap-ScaI-S4 / pUC118Sx.
- oligo DNA (SEQ ID NO: 7) containing a base sequence encoding a 7-amino acid random peptide was prepared by artificial synthesis, and was used for 3 hours at 37 ° C. with a primer (SEQ ID NO: 8) and Klenow Fragment (manufactured by Takara Bio Inc.). Double-stranded DNA was prepared from the oligo DNA by reaction. Double-stranded DNA purified using Nucleotide removal kit (Qiagen) was digested with restriction enzyme BglI (Takara Bio).
- AAV2WG-RPL / pUC118Sx is a plasmid in which this DNA is inserted into AAV2WG-Cap-ScaI-S4 / pUC118Sx digested with SfiI using DNA ligation kit ⁇ Mighty Mix> (manufactured by TAKARA BIO INC.). Used as.
- Example 2 Preparation of AAV2 Random Peptide Virus Library (1) Inoculation of AAV293 Cells After culturing AAV293 cells (Stratagene) was collected, 5% was obtained with DMEM (Sigma) containing 10% FBS and 2 mM L-glutamate. It suspended so that it might become * 10 ⁇ 4 > cell / mL. 40 mL of a solution containing AAV293 cells was added to a T225 cm 2 flask (manufactured by Corning) for cell culture, and cultured in a CO 2 incubator at 37 ° C. for 72 hours.
- AAV2WG-RPL / pUC118Sx 400 ng obtained in Example 1 and 40 ⁇ g of pHELP (manufactured by cellbiolabs) were each transfected into AAV293 cells using a general calcium phosphate method.
- the medium was completely removed, 40 mL of DMEM containing 2% FBS and 2 mM sodium L-glutamate was added, and the cells were cultured in a CO 2 incubator at 37 ° C. for 48 hours.
- AAV2 Random Peptide Virus Library 0.5 mL of 0.5M EDTA was added to a T225 cm 2 flask during culture and allowed to stand for several minutes. Thereafter, AAV293 cells were detached by pipetting and collected in a 50 mL tube. After centrifugation at 300 ⁇ g for 10 minutes, the supernatant was removed. After resuspending cells in 2 mL of TBS (Tris-buffered saline) per flask, repeat a series of treatments 3 times with ethanol / dry ice for 15 minutes, 37 ° C water bath for 15 minutes, and vortex for 1 minute. The cell disruption solution containing the AAV-random peptide virus library was collected.
- TBS Tris-buffered saline
- Example 3 Purification of AAV2 Random Peptide Virus Library (1) Purification by cesium chloride density gradient centrifugation 1 In a 40 PA tube for ultracentrifugation (manufactured by HITACHI-KOKI), 4 mL of cesium chloride solution prepared at a specific gravity of 1.5 from the bottom, 4 mL of cesium chloride solution prepared at a specific gravity of 1.25, Example 2- (4) The AAV vector solution prepared in (1) was layered in the order of 28 mL, and centrifuged at 25000 rpm, 16 ° C. for 3 hours in an ultracentrifuge HIMAC (manufactured by HITACHI KOKI).
- Example 2- (4) After centrifugation, 28 mL of the solution was removed from the top, and then 0.7 mL of each solution was collected from the top and collected in a 1.5 mL tube. In the same manner as in Example 2- (4), the titer of the AAV vector contained in each recovered solution was quantified.
- Example 3 Purification by cesium chloride density gradient centrifugation 2
- a cesium chloride solution prepared with a specific gravity of 1.39 was added and filled up to 10.5 mL. This solution was added to a 13PA tube for ultracentrifugation (manufactured by HITACHI-KOKI), and centrifuged with an ultracentrifuge at 38000 rpm, 18 ° C. for 16 hours. After centrifugation, 0.7 mL was collected in order from the top of the tube, and the contents were collected. The titer of the AAV vector in each recovered solution was quantified in the same manner as in Example 2- (4).
- Example 3- (2) Desalination by dialysis Several fractions having high titers in Example 3- (2) were mixed and added to a Slide-A-lyzer dialysis cassette (Pierce).
- the purified AAV solution was desalted by dialysis twice at 4 ° C. for 3 hours with 1 L of phosphate buffered saline (PBS) and overnight at 4 ° C. with 500 mL of PBS / 5% sorbitol solution. Thereafter, the solution was collected, sterilized with a 0.22 ⁇ m filter (Millipore), and stored at ⁇ 80 ° C. until use.
- the titer of the purified AAV solution was quantified in the same manner as in Example 2- (4).
- Example 4 Screening of AAV2 Random Peptide Library (1) Tail Vein Administration to Mice
- the purified AAV solution obtained in Example 3- (3) was adjusted to 1 ⁇ 10 13 viral genome (VG) / kg.
- NucleoSpin registered trademark
- PCR was performed 30 cycles, with 98 ° C. for 10 seconds, 55 ° C. for 15 seconds, and 68 ° C. for 15 seconds.
- DNA was purified using Nucleospin extract II (manufactured by Machalai Nagel) and cleaved using restriction enzyme BglI. After electrophoresis, the product was purified using Nucleospin extract II (manufactured by Machalai Nagel) and AAV2WG-Cap-ScaI-S4 prepared in Example 1 using DNA ligation kit ⁇ Mighty Mix> (manufactured by Takara Bio). Recloned into / pUC118Sx.
- VEEGRRGQ SEQ ID NO: 15
- GGDATRG SEQ ID NO: 16
- GDDTRG SEQ ID NO: 30
- GAMGSV SEQ ID NO: 24 and 34
- Example 5 Evaluation of directionality of AAV vector having acquired peptide sequence
- Construction of pRC-GDDTRG The AAV2WG-Cap-ScaI-S4 / pUC118Sx clone having the GDDTRG sequence obtained in Example 4- (5) was used as a restriction enzyme DNA fragmentation kit ⁇
- the helper plasmid pRC-GDDTGRG was obtained by ligation using Mighty Mix> (manufactured by Takara Bio Inc.).
- Example 5- (2) Administration of AAV Purified Solution to Mice
- the purified AAV solution obtained in Example 5- (2) was administered from the mouse tail vein so that the mouse was 1 ⁇ 10 13 VG / kg.
- Table 3 shows that the AAV vector of the capsid having the GDDTRG sequence easily migrates to the lymph nodes, and that the AAV genome is maintained even 6 weeks after administration.
- SYBR PrimeScript RT-PCR Kit manufactured by Takara Bio Inc.
- the expression level of the AsRed2 gene primer having the sequences of SEQ ID NOs: 38 and 39
- the mouse GAPDH gene SEQ ID NOs: 40 and 41
- Example 6 Evaluation of Antitumor Activity Using IL-12 Gene-Loaded AAV2 Mutant (1) Construction of pAAV2-IL12 Mouse IL-12a-p35 gene (GenBank Accession No .: NM_008351) was expressed as mIL12a-fwd primer (SEQ ID NO: 42) And cDNA prepared from mouse spleen using mIL12a-rev primer (SEQ ID NO: 43) as a template and amplified by PrimeSTAR MAX DNA Polymerase (manufactured by Takara Bio Inc.).
- the obtained amplified fragment and a vector fragment obtained by digesting pAAV-MCS Expression Vector (CELL BIOLABS) with EcoRI (Takara Bio) and BamHI (Takara Bio) were used as an In-Fusion HD Cloning Kit ( Was used to obtain pAAV2-mIL12a.
- the mouse IL-12b-p40 gene (GenBank Accession No .: NM_008352) was prepared from the mouse spleen with the mIL12b-fwd primer (SEQ ID NO: 44) and the mIL12b-rev primer (SEQ ID NO: 45) incorporating the T2A sequence.
- Amplification was performed using PrimeSTAR MAX DNA Polymerase (manufactured by Takara Bio Inc.) using cDNA as a template.
- the obtained amplified fragment and a vector fragment obtained by digesting pAAV2-mIL12a with BamHI and HindIII were ligated using In-Fusion HD Cloning Kit (Clontech) to obtain pAAV2-mIL12. That is, pAAV2-mIL12 retains a polynucleotide linked in the order of IL-12a-p35 gene, T2A, and IL-12b-p40 gene, and produces mature IL12 protein.
- pAAV-AsRed2 was transfected instead of pAAV2-mIL12 and used as a control.
- the medium was completely removed, 20 mL of DMEM containing 2% FBS and 2 mM sodium L-glutamate was added, and the cells were cultured in a CO 2 incubator at 37 ° C. for 48 hours. Thereafter, AAV vectors were produced and purified by the methods shown in Example 2- (3) and Example 3. Thereafter, the titer of the AAV vector was quantified by the method shown in Example 2- (4).
- AAV2-IL12 having a GDDTRG mutant capsid was shown to have antitumor activity.
- Example 7 Evaluation of Directivity of AAV Vector Having Acquired Peptide Sequence-2
- GGDATRG sequence SEQ ID NO: 16
- GAMGGSV sequence SEQ ID NO: 24
- Example 7- (1) Production and purification of AAV2-AsRed2 capsid mutants Using pRC-GGDATRG or pRC-GAMGGSV prepared in Example 7- (1), each capsid mutation was carried out according to the method described in Example 5- (2). AAV-AsRed2 vector having Thereafter, the titer of the AAV vector was quantified by the method shown in Example 2- (4).
- an AAV capsid protein mutant having directivity for the heart and immune organs, particularly lymph nodes, is provided, and a method for efficiently introducing genes into the lymph nodes is provided.
- SEQ ID NO: 1 AAV2 capsid 586-591 coding sequence
- SEQ ID NO: 2 Converted AAV2 capsid coding sequence
- SEQ ID NO: 3 Ampicillin resistance gene before conversion
- SEQ ID NO: 4 Ampicillin resistance gene after conversion
- SEQ ID NO: 5 AAV2 rep gene before conversion
- SEQ ID NO: 6 AAV2 rep gene after conversion
- SEQ ID NO: 7 DNA sequence coding random peptide
- SEQ ID NO: 8 Primer for synthesizing double strand DNA
- SEQ ID NO: 10 Reverse primer for quantitation of AAV titer
- SEQ ID NO: 11 Forward primer1 for amplification of random peptide coding region
- SEQ ID NO: 12 Reverse primer1 for amplification of random peptide coding region
- SEQ ID NO: 13 Forward primer2 for amplification of random peptide coding region
- SEQ ID NO: 14
Abstract
Description
[1]配列表の配列番号15、配列番号16、配列番号24及び配列番号30からなる群より選択されるアミノ酸配列を有するペプチドを含有させたアデノ随伴ウイルス(AAV)キャプシドタンパク質変異体をコードする核酸、
[2]AAVキャプシドタンパク質がAAV2由来である[1]記載の核酸、
[3]AAV2のVP1のアミノ酸番号588番に続く位置に前記ペプチドを含有させた[1]記載の核酸、
[4][1]~[3]のいずれか1項に記載の核酸を含む組換えDNA、
[5][1]~[3]のいずれか1項に記載の核酸又は[4]記載の組換えDNAを含む細胞、
[6]配列表の配列番号15、配列番号16、配列番号24及び配列番号30からなる群より選択されるアミノ酸配列を有するペプチドを含有させたAAVキャプシドタンパク質変異体を含むAAV粒子、
[7]AAVキャプシドタンパク質がAAV2由来である[6]記載のAAV粒子、
[8]AAV2のVP1のアミノ酸番号588番に続く位置に前記ペプチドを含有させた[6]記載のAAV粒子、
[9]配列表の配列番号15、配列番号16、配列番号24及び配列番号30からなる群より選択されるアミノ酸配列を有するペプチドを含有させたAAVキャプシドタンパク質変異体を含むAAV粒子を細胞に接触させる工程を含む、遺伝子導入細胞の製造方法、
[10]AAVキャプシドタンパク質がAAV2由来である[9]記載の方法、
[11]AAV2のVP1のアミノ酸番号588番に続く位置に前記ペプチドを含有させた[9]記載の方法、に関する。
本発明の核酸は、配列表の配列番号15、配列番号16、配列番号24及び配列番号30からなる群より選択されるアミノ酸配列を有するペプチドを含有させたAAVキャプシドタンパク質変異体をコードする核酸である。
本発明はまた、本発明の核酸、具体的には前記(1)の組換えDNAを含む宿主細胞、例えば単離された宿主細胞を提供する。単離された細胞は、例えばインビトロで維持されている細胞株である。本発明の宿主細胞は、以下に説明するように本発明のAAV粒子の製造に有用である。本発明の宿主細胞がAAV粒子を製造するために使用される場合、これは「パッケージング細胞」又は「プロデューサー細胞」と称することがある。本発明の宿主細胞は、前記(1)記載の本発明の組換えDNAがゲノムに組み込まれても良く、AAVキャプシドタンパク質変異体を一過性に発現するように前記の組換えDNAが細胞内に保持されていても良い。
本発明のAAV粒子は、配列表の配列番号15、配列番号16、配列番号24及び配列番号30からなる群より選択されるアミノ酸配列を有するペプチドを含有させたAAVキャプシドタンパク質変異体を含むAAV粒子である。当該AAV粒子は、前記(2)に記載される宿主細胞により製造することができる。本発明のAAV粒子は、心臓(心筋)、免疫器官(免疫細胞)、特にリンパ節に指向性を有し、傍大動脈リンパ節及び/又は大腿リンパ節への遺伝子導入に有用である。本発明のAAV粒子により導入された遺伝子は、前記組織、器官及び細胞で強く発現される。
前記(3)により得られる本発明のAAV粒子は、遺伝子治療やその他の目的で、所望の異種ポリヌクレオチドの細胞への送達のために使用される。一般にAAV粒子は、インビボ又はインビトロのいずれかで細胞へ導入される。インビトロで導入する場合、生体より取得された細胞にAAV粒子を接触させることにより導入する。この細胞を生体に移植することもできる。細胞を生体に導入する場合は、薬学的組成物として製剤化し、筋肉内、静脈内、皮下及び腹腔内投与などの様々な技術を利用できる。インビボで形質導入する場合は、AAV粒子を薬学的組成物として製剤化し、一般に非経口投与する(例えば、筋肉内、皮下、腫瘍内、経皮、髄腔内などの投与経路により投与する)。AAV粒子を含む薬学的組成物は、薬剤として許容される担体、及び必要に応じて他の薬剤、医薬品、安定化剤、緩衝液、担体、アジュバント、希釈液などを含む。
pAsRed2-C1 Vector(クロンテック社製)を鋳型として、CMVプロモーターの上流、及びpolyAシグナルの下流に制限酵素NotIの認識部位を付加した約1.6kbの断片をPCR法によって得た。このPCR産物をNotI(タカラバイオ社製)で処理してインサートDNAとした。一方pAAV-MCS Expression Vector(CELL BIOLABS社製)をNotIで処理して約2.9kbの断片を調製して、これをベクターとした。このベクターにインサートDNAをDNA Ligation Kit<Mighty Mix>(タカラバイオ社製)を用いてライゲーションし、これを用いてE.Coli HST08 Premium Competent Cells(タカラバイオ社製)を形質転換した。得られたクローンから抽出したプラスミドDNAのうち、上流からCMVプロモーター-AsRed2-MCS-polyAシグナルの順に挿入されたものをpAAV-AsRed2とした。
AAV2のゲノムを搭載したプラスミドベクターpAV1(ATCC Number:37215)を汎用宿主(Distribution host)のEscherichia coli HB101より抽出した。抽出したプラスミドから制限酵素BglII(タカラバイオ社製)によりAAV2のゲノムDNA(約4.7kb)を切り出した。このゲノムDNAをpUC118 BamHI/BAP(タカラバイオ社製)に挿入し、得られたプラスミドDNAをAAV2WG/pUC118とした。
(1)AAV293細胞の播種
培養したAAV293細胞(Stratagene社製)を回収後、10%FBS及び2mM L-グルタミン酸ナトリウムを含むDMEM(シグマ社製)で5×104細胞/mLとなるように懸濁した。細胞培養用T225cm2フラスコ(コーニング社製)にAAV293細胞を含む溶液を40mL添加し、37℃のCO2インキュベーターで72時間培養した。
実施例1で得たAAV2WG-RPL/pUC118Sx 400ng及びpHELP(cellbiolabs社製)を40μgずつを、一般的なリン酸カルシウム法を用いてAAV293細胞にトランスフェクションした。トランスフェクションの6時間後、培地を完全に除去し、2%FBS及び2mM L-グルタミン酸ナトリウムを含むDMEM 40mLを添加し、37℃のCO2インキュベーターで48時間培養した。
培養中のT225cm2フラスコに、0.5M EDTAを0.5mL添加して数分間静置した。その後、ピペッティングでAAV293細胞を剥離させて50mLチューブに回収し、300×g、10分間遠心後、上清を除去した。フラスコ1枚あたり2mLのTBS(トリス緩衝生理食塩水)に細胞を再懸濁後、エタノール/ドライアイスで15分間、37℃のウォーターバスで15分間、ボルテックス1分間の一連の処理を3回繰り返し、AAV-ランダムペプチドウイルスライブラリーを含む細胞破砕液を回収した。この溶液に、TBS1mLあたり、1M MgCl2を5μL、Benzonase(登録商標)ヌクレアーゼ(メルク社製)を終濃度200U/mLとなるように添加し、37℃で30分間反応させた。その後、0.5M EDTAをTBS1mLあたり6.5μL添加して反応を停止させた。この細胞破砕液を10000rpm、4℃、10分間遠心後、上清を回収しAAVベクター溶液とした。
AAVベクター溶液2μLに、10×DNaseIバッファー2μL、注射用水(大塚製薬社製)15.2μL、DNaseI(タカラバイオ社製)0.8μLを添加し、37℃で1時間インキュベートし、遊離のゲノムDNAやプラスミドDNAを除去した。DNaseIを不活化するために99℃、10分間の熱処理後、注射用水15μL、10×ProKバッファー[0.1M Tris-HCl (pH7.8)、0.1M EDTA、5% SDS]4μL、ProK(タカラバイオ社製)1μLを添加し、55℃で1時間インキュベートした。その後、ProKを不活化するために95℃10分間処理した。このサンプルに対し、SYBR(登録商標) Premix ExTaq2(タカラバイオ社製)及びプライマー(配列番号9及び配列番号10)を用いて、キットに添付の説明書に従いAAVの力価定量を行った。なおサンプルは、注射用水で50倍希釈した溶液を2μL用いた。また、標準品として、pAV1を制限酵素で消化し、線状化したDNAを用いた。
(1)塩化セシウム密度勾配遠心分離による精製1
超遠心用の40PAチューブ(HITACHI-KOKI社製)に、底から比重1.5に調製した塩化セシウム溶液を4mL、比重1.25に調製した塩化セシウム溶液を4mL、実施例2-(4)で調製したAAVベクター溶液を28mLの順に重層し、超遠心機HIMAC(HITACHI KOKI社製)で25000rpm、16℃、3時間遠心した。遠心後、上から28mLの溶液を除き、続いて上から0.7mLずつ溶液を採取して1.5mLチューブにそれぞれ回収した。実施例2-(4)と同様の方法で、各回収液に含まれるAAVベクターの力価を定量した。
実施例3-(1)で力価の高かった数フラクションに、比重1.39に調製した塩化セシウム溶液を加えて、10.5mLにフィルアップした。この溶液を超遠心用13PAチューブ(HITACHI-KOKI社製)に添加し、超遠心機で38000rpm、18℃、16時間遠心した。遠心後、チューブの上から順に0.7mLずつ採取して内容液を回収した。各回収液のAAVベクターの力価を実施例2-(4)と同様の方法で定量した。
実施例3-(2)で力価の高かった数フラクションを混合し、Slide-A-lyzer透析カセット(Pierce社製)に添加した。リン酸緩衝生理食塩水(PBS)1Lにより4℃で3時間の透析を2回、PBS/5%ソルビトール溶液500mLにより4℃で一晩透析を行うことで精製AAV溶液の脱塩を行った。その後、溶液を回収し、0.22μmフィルター(ミリポア社製)で滅菌後、使用するまで-80℃で保存した。また別途、精製AAV溶液の力価を実施例2-(4)と同様の方法で定量した。
(1)マウスへの尾静脈投与
実施例3-(3)で得られた精製AAV溶液を、1×1013ウイルスゲノム(VG)/kgとなるように、BALB/cマウスの尾静脈から投与した。投与72時間後に鼠径リンパ節及び傍大動脈リンパ節を回収し、NucleoSpin(登録商標) tissue(マッハライ・ナーゲル社製)を用いてゲノムDNAを抽出した(ラウンド1)。
実施例4-(1)で抽出したゲノムDNAを鋳型とし、PrimeSTAR(登録商標) GXL DNA polymerase(タカラバイオ社製)を用いてランダムペプチド配列をコードするDNAを増幅した。プライマーはフォワードプライマー1(配列番号11)及びリバースプライマー1(配列番号12)を用いた。PCRを98℃10秒、55℃15秒、68℃40秒を1サイクルとして30サイクル繰り返した。続いて、この反応液の1/25量を用いてフォワードプライマー2(配列番号13)及びリバースプライマー2(配列番号14)を用いて同量の反応液を調製した。PCRを98℃10秒、55℃15秒、68℃15秒を1サイクルとして30サイクル実施した。この反応液からNucleospin extract II(マッハライ・ナーゲル社製)を用いてDNAを精製し、制限酵素BglIを用いて切断した。電気泳動後、Nucleospin extract II(マッハライ・ナーゲル社製)を用いて精製し、DNA ligation kit<Mighty Mix>(タカラバイオ社製)を用いて、実施例1で調製したAAV2WG-Cap-ScaI-S4/pUC118Sxにリクローニングした。
実施例4-(2)で得たプラスミドを使用し、実施例2及び実施例3と同様の方法で、AAV2ランダムペプチドウイルスライブラリーの製造と精製を行った。
実施例4-(1)と同様の方法でスクリーニングを行い、ゲノムDNAを抽出した(ラウンド2)。さらに、抽出したゲノムDNAを使用して、再度リクローニング、ライブラリー製造と精製及びスクリーニングを行いゲノムDNAを抽出した(ラウンド3)。
各スクリーニング段階(ラウンド1~ラウンド3)のAAVランダムペプチドプラスミドライブラリーのシークエンスを90数クローンずつ行った。そのうち複数回出現したクローンのペプチド配列と出現回数を、傍大動脈リンパ節から回収したクローンについて表1に、大腿リンパ節から回収したクローンについて表2に示す。
(1)pRC-GDDGTRGの構築
実施例4-(5)で得られたGDDGTRG配列を持つAAV2WG-Cap-ScaI-S4/pUC118Sxクローンを制限酵素SnaBI(タカラバイオ社製)とHindIII(タカラバイオ社製)で消化して得た断片と、pAAVRC2ベクター(CELL BIOLABS社製)をSnaBIとHindIIIで消化して得たベクター断片を、DNA ligation kit<Mighty Mix>(タカラバイオ社製)により連結し、ヘルパープラスミドpRC-GDDGTRGを得た。
調製例1で作製したpAAV-AsRed2、pHELP及び実施例5-(1)で調製したpRC-GDDGTRGとをそれぞれ25μgずつを、一般的なリン酸カルシウム法を用いてT225cm2に播種しておいたAAV293細胞にトランスフェクションした。なお、pRC-GDDGTRGの代わりに野生型キャプシドを搭載したpAAVRC2ベクターをトランスフェクションし、対照とした。トランスフェクションの6時間後、培地を完全に除去し、2%FBS及び2mM L-グルタミン酸ナトリウムを含むDMEM40mLを添加し、37℃のCO2インキュベーターで48時間培養した。その後、実施例2-(3)、実施例3に示した方法で、2種類のAAV-AsRed2ベクターを製造・精製した。その後、実施例2-(4)に示した方法で、AAVベクターの力価を定量した。
マウス一匹当たり1×1013VG/kgとなるように、マウス尾静脈から実施例5-(2)で得た精製AAV溶液を投与した。
実施例5-(3)でAAVを投与したマウスを、1週間後、又は6週間後に安楽死させ、各組織を回収した。NucleoSpin tissue(マッハライ・ナーゲル社製)を用いて、各組織からゲノムDNAを抽出した。抽出したゲノムDNAをサンプルとしてリアルタイムPCRを実施し、各組織中に含まれるAAVベクターゲノム量を定量した。各組織中の全ゲノムDNA1μg当たりのAAVゲノムDNAの分子数を表3に示す。
実施例5-(4)で得た各組織をRNA later(キアゲン社製)に浸して4℃で一晩反応させた。その後、バイオマッシャーII(ニッピ社製)を用いてホモジナイズを行い、NucleoSpin RNA II(マッハライ・ナーゲル社製)でRNAを抽出した。Onestep SYBR PrimeScript RT-PCR Kit(タカラバイオ社製)を用いて、AsRed2遺伝子(配列番号38及び39の配列を有するプライマー)の発現量及び補正用としてマウスGAPDH遺伝子(配列番号40及び41の配列を有するプライマー)の発現量を定量した。AsRed2発現量をGAPDH発現量で補正した結果を表4に記載する。
(1)pAAV2-IL12の構築
マウスIL-12a-p35遺伝子(GenBank Accession No.:NM_008351)をmIL12a-fwdプライマー(配列番号42)及びmIL12a-revプライマー(配列番号43)により、マウス脾臓より調製したcDNAを鋳型にして、PrimeSTAR MAX DNA Polymerase(タカラバイオ社製)により増幅した。得られた増幅断片と、pAAV-MCS Expression Vector(CELL BIOLABS社製)をEcoRI(タカラバイオ社製)とBamHI(タカラバイオ社製)で消化し得たベクター断片を、In-Fusion HD Cloning Kit(クロンテック社製)を用いて連結し、pAAV2-mIL12aを得た。続いてマウスIL-12b-p40遺伝子(GenBank Accession No.:NM_008352)を、T2A配列を組み込んだmIL12b-fwdプライマー(配列番号44)及びmIL12b-revプライマー(配列番号45)により、マウス脾臓より調製したcDNAを鋳型にして、PrimeSTAR MAX DNA Polymerase(タカラバイオ社製)により増幅した。得られた増幅断片と、pAAV2-mIL12aをBamHIとHindIIIで消化し得たベクター断片を、In-Fusion HD Cloning Kit(クロンテック社製)を用いて連結しpAAV2-mIL12を得た。すなわち、pAAV2-mIL12はIL-12a-p35遺伝子、T2A、IL-12b-p40遺伝子の順に連結されたポリヌクレオチドを保持しており、成熟型IL12タンパクを産生する。
実施例6-(1)で調製したpAAV2-mIL12、pHELP及び実施例5-(1)で調製したpRC-GDDGTRGのそれぞれ25μgずつを、一般的なリン酸カルシウム法を用いて、T225cm2に播種しておいたAAV293細胞にトランスフェクションした。なお、pAAV2-mIL12の代わりにpAAV-AsRed2をトランスフェクションし、コントロールとした。トランスフェクション6時間後、培地を完全に除去し、2%FBS及び2mM L-グルタミン酸ナトリウムを含むDMEM 20mLを添加し、37℃のCO2インキュベーターで48時間培養した。その後、実施例2-(3)、実施例3に示した方法で、AAVベクターを製造・精製した。その後、実施例2-(4)に示した方法で、AAVベクターの力価を定量した。
マウス一匹当たり5×1013VG/kgとなるように、マウス尾静脈から精製AAV溶液を投与した。投与の2週間後、マウス背部皮下にCT26腫瘍細胞株をマウス一匹あたり1×106細胞投与した。その後、継時的に腫瘍サイズを定量した。各測定日における腫瘍サイズの平均値を表5に示す。
(1)pRC-GGDATRG、pRC-GAMGGSVの構築
実施例4-(5)で得られたGGDATRG配列(配列番号16)あるいはGAMGGSV配列(配列番号24)を持つAAV2WG-Cap-ScaI-S4/pUC118Sxクローンから、実施例5-(1)と同様の方法によりヘルパープラスミドpRC-GGDATRG及びpRC-GAMGGSVを得た。
実施例7-(1)で調製したpRC-GGDATRGあるいはpRC-GAMGGSVを用いて、実施例5-(2)で示した方法によりそれぞれのキャプシド変異を持つAAV-AsRed2ベクターを製造・精製した。その後、実施例2-(4)に示した方法で、AAVベクターの力価を定量した。
マウス一匹当たり1×1011VGとなるように、マウス尾静脈から精製AAV溶液を投与した。この際、実施例5-(2)で調製した野生型あるいはGDDGTRG変異を持つAAVベクターを投与した群を設定した。
実施例7-(3)でAAVを投与したマウスを、6週間後に安楽死させ、各組織を回収し、RNA later(キアゲン社製)に浸して4℃で一晩反応させた。その後、実施例5-(5)と同様の方法によりRNAを調製し、Onestep SYBR PrimeScript PLUS RT-PCR Kit(タカラバイオ社製)を用いて、AsRed2遺伝子(配列番号38及び39の配列を有するプライマー)の発現量及び補正用としてマウスGAPDH遺伝子(配列番号40及び41の配列を有するプライマー)の発現量を定量した。AsRed2発現量をGAPDH発現量で補正した結果を表6に記載する。
また、上記の結果から、各スクリーニング段階(ラウンド1~3)で、プラスミドライブラリーのシークエンスを90数クローン行い、複数回出現したペプチド配列は、リンパ節又は心臓に高い指向性を有することが確認された。
SEQ ID NO:2: Converted AAV2 capsid coding sequence
SEQ ID NO:3: Ampicillin resistance gene before conversion
SEQ ID NO:4: Ampicillin resistance gene after conversion
SEQ ID NO:5: AAV2 rep gene before conversion
SEQ ID NO:6: AAV2 rep gene after conversion
SEQ ID NO:7: DNA sequence coding random peptide
SEQ ID NO:8: Primer for synthesizing double strand DNA
SEQ ID NO:9: Forward primer for quantitation of AAV titer
SEQ ID NO:10: Reverse primer for quantitation of AAV titer
SEQ ID NO:11: Forward primer1 for amplification of random peptide coding region
SEQ ID NO:12: Reverse primer1 for amplification of random peptide coding region
SEQ ID NO:13: Forward primer2 for amplification of random peptide coding region
SEQ ID NO:14: Reverse primer2 for amplification of random peptide coding region
SEQ ID NO:15: Peptide sequence comprised AAV capsid protein mutant
SEQ ID NO:16: Peptide sequence comprised AAV capsid protein mutant
SEQ ID NO:17: Peptide sequence comprised AAV capsid protein mutant
SEQ ID NO:18: Peptide sequence comprised AAV capsid protein mutant
SEQ ID NO:19: Peptide sequence comprised AAV capsid protein mutant
SEQ ID NO:20: Peptide sequence comprised AAV capsid protein mutant
SEQ ID NO:21: Peptide sequence comprised AAV capsid protein mutant
SEQ ID NO:22: Peptide sequence comprised AAV capsid protein mutant
SEQ ID NO:23: Peptide sequence comprised AAV capsid protein mutant
SEQ ID NO:24: Peptide sequence comprised AAV capsid protein mutant
SEQ ID NO:25: Peptide sequence comprised AAV capsid protein mutant
SEQ ID NO:26: Peptide sequence comprised AAV capsid protein mutant
SEQ ID NO:27: Peptide sequence comprised AAV capsid protein mutant
SEQ ID NO:28: Peptide sequence comprised AAV capsid protein mutant
SEQ ID NO:29: Peptide sequence comprised AAV capsid protein mutant
SEQ ID NO:30: Peptide sequence comprised AAV capsid protein mutant
SEQ ID NO:31: Peptide sequence comprised AAV capsid protein mutant
SEQ ID NO:32: Peptide sequence comprised AAV capsid protein mutant
SEQ ID NO:33: Peptide sequence comprised AAV capsid protein mutant
SEQ ID NO:34: Peptide sequence comprised AAV capsid protein mutant
SEQ ID NO:35: Peptide sequence comprised AAV capsid protein mutant
SEQ ID NO:36: Peptide sequence comprised AAV capsid protein mutant
SEQ ID NO:37: Peptide sequence comprised AAV capsid protein mutant
SEQ ID NO:38: Forward primer for amplifivation of AsRed2
SEQ ID NO:39: Reverse primer for amplifivation of AsRed2
SEQ ID NO:40: Forward primer for amplifivation of mouse GAPDH
SEQ ID NO:41: Reverse primer for amplifivation of mouse GAPDH
SEQ ID NO:42: mIL12a-fwd primer
SEQ ID NO:43: mIL12a-rev primer
SEQ ID NO:44: mIL12b-fwd primer
SEQ ID NO:45: mIL12b-rev primer
Claims (11)
- 配列表の配列番号15、配列番号16、配列番号24及び配列番号30からなる群より選択されるアミノ酸配列を有するペプチドを含有させたアデノ随伴ウイルス(AAV)キャプシドタンパク質変異体をコードする核酸。
- AAVキャプシドタンパク質がAAV2由来である請求項1記載の核酸。
- AAV2のVP1のアミノ酸番号588番に続く位置に前記ペプチドを含有させた請求項1記載の核酸。
- 請求項1~3のいずれか1項に記載の核酸を含む組換えDNA。
- 請求項1~3のいずれか1項に記載の核酸又は請求項4記載の組換えDNAを含む細胞。
- 配列表の配列番号15、配列番号16、配列番号24及び配列番号30からなる群より選択されるアミノ酸配列を有するペプチドを含有させたAAVキャプシドタンパク質変異体を含むAAV粒子。
- AAVキャプシドタンパク質がAAV2由来である請求項6記載のAAV粒子。
- AAV2のVP1のアミノ酸番号588番に続く位置に前記ペプチドを含有させた請求項6記載のAAV粒子。
- 配列表の配列番号15、配列番号16、配列番号24及び配列番号30からなる群より選択されるアミノ酸配列を有するペプチドを含有させたAAVキャプシドタンパク質変異体を含むAAV粒子を細胞に接触させる工程を含む、遺伝子導入細胞の製造方法。
- AAVキャプシドタンパク質がAAV2由来である請求項9記載の方法。
- AAV2のVP1のアミノ酸番号588番に続く位置に前記ペプチドを含有させた請求項9記載の方法。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014554421A JP6363958B2 (ja) | 2012-12-25 | 2013-12-20 | Aav変異体 |
US14/649,603 US9938541B2 (en) | 2012-12-25 | 2013-12-20 | AAV variant |
EP13867056.7A EP2940131B1 (en) | 2012-12-25 | 2013-12-20 | Aav variant |
CN201380067755.7A CN104937100B (zh) | 2012-12-25 | 2013-12-20 | Aav 变体 |
HK16102758.0A HK1215277A1 (zh) | 2012-12-25 | 2016-03-10 | 變體 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012-280485 | 2012-12-25 | ||
JP2012280485 | 2012-12-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014103957A1 true WO2014103957A1 (ja) | 2014-07-03 |
Family
ID=51021040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/084336 WO2014103957A1 (ja) | 2012-12-25 | 2013-12-20 | Aav変異体 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9938541B2 (ja) |
EP (1) | EP2940131B1 (ja) |
JP (1) | JP6363958B2 (ja) |
CN (1) | CN104937100B (ja) |
HK (1) | HK1215277A1 (ja) |
WO (1) | WO2014103957A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017197355A2 (en) | 2016-05-13 | 2017-11-16 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and methods of use thereof |
WO2018139634A1 (ja) | 2017-01-30 | 2018-08-02 | 学校法人日本医科大学 | アデノ随伴ウイルス(aav)キャプシドタンパク質の変異体 |
WO2019060454A2 (en) | 2017-09-20 | 2019-03-28 | 4D Molecular Therapeutics Inc. | CAPSID VARIANT ADENO-ASSOCIATED VIRUSES AND METHODS OF USE |
WO2019104279A1 (en) | 2017-11-27 | 2019-05-31 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and use for inhibiting angiogenesis |
WO2020174369A2 (en) | 2019-02-25 | 2020-09-03 | Novartis Ag | Compositions and methods to treat bietti crystalline dystrophy |
WO2020174368A1 (en) | 2019-02-25 | 2020-09-03 | Novartis Ag | Compositions and methods to treat bietti crystalline dystrophy |
WO2020218419A1 (ja) * | 2019-04-24 | 2020-10-29 | タカラバイオ株式会社 | 脳に指向性を有するaav変異体 |
RU2809389C2 (ru) * | 2019-04-24 | 2023-12-11 | Такара Байо Инк. | Мутант aav, обладающий способностью нацеливаться на головной мозг |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
SG10202110919YA (en) | 2011-04-22 | 2021-11-29 | Univ California | Adeno-associated virus virions with variant capsid and methods of use thereof |
US11136557B2 (en) | 2013-05-31 | 2021-10-05 | The Regents Of The University Of California | Adeno-associated virus variants and methods of use thereof |
US10000741B2 (en) | 2014-03-17 | 2018-06-19 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression in cone cells |
EP3151866B1 (en) | 2014-06-09 | 2023-03-08 | Voyager Therapeutics, Inc. | Chimeric capsids |
EP3215191A4 (en) | 2014-11-05 | 2018-08-01 | Voyager Therapeutics, Inc. | Aadc polynucleotides for the treatment of parkinson's disease |
CN114717264A (zh) | 2014-11-14 | 2022-07-08 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
JP6863891B2 (ja) | 2014-11-14 | 2021-04-21 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | 調節性ポリヌクレオチド |
US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
JP7095994B2 (ja) | 2015-03-02 | 2022-07-05 | アドヴェラム バイオテクノロジーズ, インコーポレイテッド | ポリヌクレオチドを網膜錐体に硝子体内送達するための組成物及び方法 |
AU2016235163B2 (en) | 2015-03-24 | 2022-03-24 | The Regents Of The University Of California | Adeno-associated virus variants and methods of use thereof |
US10983110B2 (en) | 2015-12-02 | 2021-04-20 | Voyager Therapeutics, Inc. | Assays for the detection of AAV neutralizing antibodies |
US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
BR112018073384A2 (pt) | 2016-05-18 | 2019-03-06 | Voyager Therapeutics, Inc. | polinucleotídeos moduladores |
WO2017201258A1 (en) | 2016-05-18 | 2017-11-23 | Voyager Therapeutics, Inc. | Compositions and methods of treating huntington's disease |
KR20230039779A (ko) | 2016-07-29 | 2023-03-21 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 변이체 캡시드를 갖는 아데노-관련된 바이러스 비리온 및 이의 사용 방법 |
EP3506817A4 (en) | 2016-08-30 | 2020-07-22 | The Regents of The University of California | METHOD FOR BIOMEDICAL TARGETING AND RELEASE, AND DEVICES AND SYSTEMS FOR IMPLEMENTING THEM |
CA3040179A1 (en) | 2016-10-19 | 2018-04-26 | Adverum Biotechnologies, Inc. | Modified aav capsids and uses thereof |
US11752181B2 (en) | 2017-05-05 | 2023-09-12 | Voyager Therapeutics, Inc. | Compositions and methods of treating Huntington's disease |
WO2018204786A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
MX2019010910A (es) * | 2017-06-30 | 2019-11-07 | Univ California | Viriones de virus adenoasociados con capsides variantes y metodos para su uso. |
JP7229989B2 (ja) | 2017-07-17 | 2023-02-28 | ボイジャー セラピューティクス インコーポレイテッド | 軌道アレイガイドシステム |
US11680249B2 (en) | 2017-08-28 | 2023-06-20 | The Regents Of The University Of California | Adeno-associated virus capsid variants and methods of use thereof |
WO2019079240A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
US20200237799A1 (en) | 2017-10-16 | 2020-07-30 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
US10610606B2 (en) | 2018-02-01 | 2020-04-07 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
EP3755795A4 (en) | 2018-02-19 | 2022-07-20 | Homology Medicines, Inc. | ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR RECOVERING F8 GENE FUNCTION AND METHODS OF USE THEREOF |
CA3166374A1 (en) * | 2019-12-31 | 2021-07-08 | Swanbio Therapeutics Limited | Improved aav-abcd1 constructs and use for treatment or prevention of adrenoleukodystrophy (ald) and/or adrenomyeloneuropathy (amn) |
TW202140791A (zh) | 2020-01-13 | 2021-11-01 | 美商霍蒙拉奇醫藥公司 | 治療苯酮尿症之方法 |
US20230203102A1 (en) | 2020-05-13 | 2023-06-29 | Voyager Therapeutics, Inc. | Redirection of tropism of aav capsids |
CN111850045B (zh) * | 2020-07-16 | 2022-03-08 | 四川大学 | 靶向心脏血管内皮的腺相关病毒载体及其应用 |
CN113754727B (zh) * | 2020-09-30 | 2022-07-12 | 广州派真生物技术有限公司 | 腺相关病毒突变体及其应用 |
CN114057840B (zh) * | 2021-10-14 | 2022-09-20 | 和元生物技术(上海)股份有限公司 | 包含变异的aav9衣壳蛋白的重组腺相关病毒颗粒 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005512569A (ja) * | 2001-12-21 | 2005-05-12 | メディジーン・アクチェンゲゼルシャフト | 目的とする細胞指向性をもつウイルスクローンの同定に有用な修飾した構造遺伝子またはキャプシド修飾した粒子のライブラリー |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001064835A2 (en) * | 2000-02-28 | 2001-09-07 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
EP1212075A4 (en) * | 1999-08-26 | 2005-11-23 | Keith M Skubitz | PEPTIDES CAPABLE OF MODULATING THE FUNCTION OF MEMBERS OF THE CD66 FAMILY (CEACAM) |
US7749492B2 (en) * | 2001-01-05 | 2010-07-06 | Nationwide Children's Hospital, Inc. | AAV vectors and methods |
US20040002159A1 (en) * | 2002-04-05 | 2004-01-01 | Weidong Xiao | Methods for the production of chimeric adeno-associated virus (AAV) vectors, compositions of chimeric AAV vectors, and methods of use thereof |
ES2634118T3 (es) * | 2009-02-11 | 2017-09-26 | The University Of North Carolina At Chapel Hill | Vectores de virus modificados y métodos para fabricar y utilizar los mismos |
US8927514B2 (en) * | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
-
2013
- 2013-12-20 JP JP2014554421A patent/JP6363958B2/ja active Active
- 2013-12-20 WO PCT/JP2013/084336 patent/WO2014103957A1/ja active Application Filing
- 2013-12-20 US US14/649,603 patent/US9938541B2/en active Active
- 2013-12-20 CN CN201380067755.7A patent/CN104937100B/zh active Active
- 2013-12-20 EP EP13867056.7A patent/EP2940131B1/en active Active
-
2016
- 2016-03-10 HK HK16102758.0A patent/HK1215277A1/zh unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005512569A (ja) * | 2001-12-21 | 2005-05-12 | メディジーン・アクチェンゲゼルシャフト | 目的とする細胞指向性をもつウイルスクローンの同定に有用な修飾した構造遺伝子またはキャプシド修飾した粒子のライブラリー |
Non-Patent Citations (11)
Title |
---|
ADACHI K. ET AL., GENEN THER. REGUL., vol. 5, 2010, pages 31 - 55 |
GAO ET AL., J. VIROLOGY, vol. 78, 2004, pages 6381 - 6388 |
GAO ET AL., PROC. NATL. ACAD. SCI. USA, vol. 99, no. 18, 2002, pages 11854 - 11859 |
GIROD, A. ET AL.: "Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2.", NAT. MED., vol. 5, no. 9, 1999, pages 1052 - 1056, XP002128040 * |
GRIFMAN, M. ET AL.: "Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids.", MOL. THER., vol. 3, no. 6, 2001, pages 964 - 975, XP002235294 * |
HUMAN GENE THERAPY, vol. 5, 1994, pages 793 - 801 |
MULLER, O. J. ET AL.: "Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors.", NAT. BIOTECHNOL., vol. 21, no. 9, 2003, pages 1040 - 1046, XP002297275 * |
NAUMER, M. ET AL.: "Development and validation of novel AAV2 random libraries displaying peptides of diverse lengths and at diverse capsid positions.", HUM. GENE THER., vol. 23, 2012, pages 492 - 507, XP055255147 * |
See also references of EP2940131A4 |
WATERKAMP, D. A. ET AL.: "Isolation of targeted AAV2 vectors from novel virus display libraries.", J. GENE MED., vol. 8, 2006, pages 1307 - 1319, XP002596752 * |
WU, P. ET AL.: "Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism.", J. VIROL., vol. 74, no. 18, 2000, pages 8635 - 8647, XP001028219 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4209501A1 (en) | 2016-05-13 | 2023-07-12 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and methods of use thereof |
US11179477B2 (en) | 2016-05-13 | 2021-11-23 | 4D Molecular Therapeutics Inc. | Method of using adeno-associated virus with variant capsid |
WO2017197355A2 (en) | 2016-05-13 | 2017-11-16 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and methods of use thereof |
EP4206216A1 (en) | 2016-05-13 | 2023-07-05 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and methods of use thereof |
JP2019518458A (ja) * | 2016-05-13 | 2019-07-04 | 4ディー モレキュラー セラピューティクス インコーポレイテッド | アデノ関連ウイルス変異キャプシドおよびその使用方法 |
US11419949B2 (en) | 2016-05-13 | 2022-08-23 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and methods of use thereof |
US11364308B2 (en) | 2016-05-13 | 2022-06-21 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and methods of use thereof |
US11167041B2 (en) | 2016-05-13 | 2021-11-09 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and methods of use thereof |
KR20190111966A (ko) | 2017-01-30 | 2019-10-02 | 각꼬호우징 닛뽄 이까다이가꾸 | 아데노 관련 바이러스(aav) 캡시드 단백질의 돌연변이체 |
WO2018139634A1 (ja) | 2017-01-30 | 2018-08-02 | 学校法人日本医科大学 | アデノ随伴ウイルス(aav)キャプシドタンパク質の変異体 |
US11028131B2 (en) | 2017-01-30 | 2021-06-08 | Nippon Medical School Foundation | Mutant of adeno-associated virus (AAV) capsid protein |
WO2019060454A2 (en) | 2017-09-20 | 2019-03-28 | 4D Molecular Therapeutics Inc. | CAPSID VARIANT ADENO-ASSOCIATED VIRUSES AND METHODS OF USE |
EP4218828A2 (en) | 2017-09-20 | 2023-08-02 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and methods of use thereof |
EP4219695A2 (en) | 2017-11-27 | 2023-08-02 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and use for inhibiting angiogenesis |
WO2019104279A1 (en) | 2017-11-27 | 2019-05-31 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and use for inhibiting angiogenesis |
EP4272728A2 (en) | 2017-11-27 | 2023-11-08 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and use for inhibiting angiogenesis |
WO2020174368A1 (en) | 2019-02-25 | 2020-09-03 | Novartis Ag | Compositions and methods to treat bietti crystalline dystrophy |
WO2020174369A2 (en) | 2019-02-25 | 2020-09-03 | Novartis Ag | Compositions and methods to treat bietti crystalline dystrophy |
RU2809389C2 (ru) * | 2019-04-24 | 2023-12-11 | Такара Байо Инк. | Мутант aav, обладающий способностью нацеливаться на головной мозг |
WO2020218419A1 (ja) * | 2019-04-24 | 2020-10-29 | タカラバイオ株式会社 | 脳に指向性を有するaav変異体 |
Also Published As
Publication number | Publication date |
---|---|
HK1215277A1 (zh) | 2016-08-19 |
US9938541B2 (en) | 2018-04-10 |
US20150315610A1 (en) | 2015-11-05 |
EP2940131A1 (en) | 2015-11-04 |
CN104937100B (zh) | 2020-04-03 |
JPWO2014103957A1 (ja) | 2017-01-12 |
JP6363958B2 (ja) | 2018-07-25 |
EP2940131A4 (en) | 2016-06-01 |
EP2940131B1 (en) | 2019-02-20 |
CN104937100A (zh) | 2015-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6363958B2 (ja) | Aav変異体 | |
US20230295659A1 (en) | TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs) | |
WO2020218419A1 (ja) | 脳に指向性を有するaav変異体 | |
KR102167668B1 (ko) | 고 형질도입 효율 raav 벡터, 조성물 및 사용 방법 | |
JP4860886B2 (ja) | 二本鎖パルボウイルスベクター | |
JP2018515096A (ja) | 神経成長因子シグナルペプチド及び副甲状腺ホルモンを含むaav分離株及び融合タンパク質 | |
JP7081767B2 (ja) | アデノ随伴ウイルス(aav)キャプシドタンパク質の変異体 | |
CN112566923A (zh) | 合成嗜肝性腺相关病毒衣壳及其用途 | |
KR20230034211A (ko) | 변형된 아데노-관련 바이러스 5 캡시드 및 이의 용도 | |
WO2021113634A1 (en) | Transgene cassettes designed to express a human mecp2 gene | |
JP7304878B2 (ja) | キャプシド改変による組織特異的遺伝子送達の増加 | |
RU2809389C2 (ru) | Мутант aav, обладающий способностью нацеливаться на головной мозг | |
EP3810635A1 (en) | Aav polynucleotides, polypeptides and virions | |
US11891617B1 (en) | Modified complex platform of adeno-associated virus with improved rate of expression of loaded genes and reduced genotoxicity | |
JP6473438B2 (ja) | プロモーター組成物 | |
WO2020187272A1 (zh) | 一种用于基因治疗的融合蛋白及其应用 | |
WO2020187268A1 (zh) | 一种增强基因编辑的融合蛋白及其应用 | |
US20130317093A1 (en) | Methods of treating alzheimer's disease with apo a-1 milano | |
CA3219795A1 (en) | Recombinant tert-encoding viral genomes and vectors | |
CN117886897A (zh) | 一种腺相关病毒变体及其应用 | |
OA21075A (en) | Codon-optimized nucleic acid that encodes SMN1 protein, and use thereof | |
CN117836312A (zh) | 分离的修饰的aav9衣壳蛋白vp1 | |
CN117886898A (zh) | 腺相关病毒变体及其应用 | |
US20160237141A1 (en) | Methods of treating alzheimer's disease with apo a-1 milano |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13867056 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014554421 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013867056 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14649603 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |